^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

413 - Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients (Pts) with Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial

Published date:
01/13/2021
Excerpt:
...ORR/CR rates were as follows: Ibr 94%/65%; Acala 80%/40%; both 100%/100%. The 12-mo survival rates in pts with prior Ibr, Acala, or both were 81%, 80%, or 100%, respectively. Grade ≥ 3 CRS/NEs occurred as follows: Ibr 17%/31%; Acala 10%/10%; both 0/67%. All subgroups drew clinical benefit from KTE-X19 treatment despite some pharmacological differences.
Trial ID: